Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.

@article{Maccaferri2010RifaximinMT,
  title={Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.},
  author={Simone Maccaferri and Beatrice Vitali and Annett Klinder and Sofia Kolida and Maurice Ndagijimana and Luca Laghi and Fiorella Calanni and Patrizia Brigidi and Glenn R M Gibson and Adele Costabile},
  journal={The Journal of antimicrobial chemotherapy},
  year={2010},
  volume={65 12},
  pages={2556-65}
}
OBJECTIVES Rifaximin, a rifamycin derivative, has been reported to induce clinical remission of active Crohn's disease (CD), a chronic inflammatory bowel disorder. In order to understand how rifaximin affects the colonic microbiota and its metabolism, an in vitro human colonic model system was used in this study. METHODS We investigated the impact of the administration of 1800 mg/day of rifaximin on the faecal microbiota of four patients affected by colonic active CD [Crohn's disease activity… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 70 references

Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model

  • SD Baines, R O’Connor, K Saxton
  • Antimicrob Agents Chemother
  • 2009

Similar Papers

Loading similar papers…